Janssen, a part of Johnson and Johnson, warned healthcare professionals in South Africa of the risks of blood clotting disorders triggered by the COVID-19 vaccine, in a medicine safety information announcement released on October 26, 2021. TrialSite has followed the development of this vaccine from its early stages and through its promising clinical trials. However, the October statement highlights the risks of immune thrombocytopenia (ITP) and venous thromboembolism (VTE) following vaccination with the Janssen product.
The Janssen COVID-19 vaccine is approved for use in a number of countries worldwide, including the US, where it was issued Emergency Use Authorization (EUA) in February 2021. Over 15m doses were administered in the US alone by the end of October 2021. The vaccine is popular because of only requiring a single dose, as well as the company’s commitment to releasing the vaccine on a not-for-profit basis.
However, the vaccine’s roll-out has not been smooth. The US Food and Drug Administration (FDA) and Centers for Disease Control and Prevention (CDC) paused use of the vaccine in April 2021, after six serious advers...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).